Generics and Biologics in the MENA Region: Unpacking the Future of Healthcare Innovation

Generics are pharmaceutical drugs equivalent to branded products in dosage, strength, and intended use but are produced and sold at significantly lower prices once the patent for the branded drug expires. These drugs are critical in reducing healthcare costs and making treatment more accessible to patients across all socioeconomic strata. Conversely, biologics are complex drugs derived from living cells and designed to target specific diseases, such as cancer and autoimmune disorders. With technological advancements, biosimilars—highly similar and cost-effective versions of biologics—are becoming integral to healthcare systems globally, including in the MENA region.

he demand for both generics and biologics is growing due to rising population needs and increased disease prevalence in the MENA region. Governments and healthcare providers are increasingly balancing cost-effectiveness with the need for cutting-edge treatments. This dual focus highlights the complementary roles of generics for widespread, affordable care and biologics for tackling more complex, life-threatening conditions.

Market Trends and Growth Projections of Generics and Biologics in the MENA Region

The pharmaceutical market in the MENA region is experiencing dynamic growth, driven by government reforms, rising healthcare demands, and advancements in medicine manufacturing. Generics are becoming a cornerstone of healthcare strategies across the region, as countries like Saudi Arabia and the UAE prioritize local production to reduce reliance on imports and enhance medication accessibility. Saudi Arabia, under Vision 2030, is expanding its pharmaceutical sector through initiatives such as supporting generic drug procurement and fostering clinical trials. Similarly, Iran stands out with its robust production of generic medicines, satisfying domestic needs and offering a model for cost-effective healthcare. Other nations like Jordan and Algeria are also promoting generics to balance rising healthcare demands with budget constraints, with Jordan notably leading in high-quality yet affordable generics production.

Biologics and biosimilars are emerging as high-growth segments in the MENA market, reflecting global trends. Between 2015 and 2019, biologics in the region reached a market value of $4.1 billion, with a 14.5% annual growth rate. Saudi Arabia is a leader in biologics sales, contributing over $1.8 billion, followed by Egypt, the UAE, and Algeria. Biosimilars, with their cost-effectiveness and increasing acceptance, are projected to grow at a CAGR of 24.96% between 2021 and 2026, propelled by rising healthcare expenditures and demand for innovative treatments. Together, generics and biologics represent not only the region’s commitment to accessible healthcare but also its potential to become a pharmaceutical innovation hub.

Regulatory Landscape for Biologics and Generics in the MENA Region

The regulatory framework for biologics and generics in the MENA region reflects a mix of international standards and localized adaptations. Biologics, due to their complexity, require a rigorous approval process involving extensive clinical, analytical, and pharmacovigilance assessments. Regulatory bodies like the Saudi Food and Drug Authority (SFDA) and others across MENA adhere to guidelines modeled on international standards from the FDA and EMA. However, these frameworks are tailored to address regional healthcare priorities and challenges. For instance, the SFDA integrates specific Gulf Cooperation Council requirements to streamline the approval of biologics within the region. Despite these adaptations, inconsistent regulatory pathways across MENA can delay biosimilar development, creating hurdles in achieving uniform confidence in their efficacy and safety.

For generics, the landscape is shaped by increasing localization efforts, with governments promoting domestic production to reduce dependency on imports and enhance medication accessibility. While countries like the UAE and Jordan exhibit streamlined processes for generic approvals, others face regulatory bottlenecks, leading to slower adoption. Across the region, evolving regulatory reforms, such as price controls and clinical trial requirements, present both challenges and opportunities. Effective engagement with stakeholders and harmonization of regional guidelines could bridge existing gaps and accelerate the adoption of both biologics and generics, enhancing healthcare outcomes.

Advancements in Generic Drug Manufacturing

Generic drug manufacturing is on the rise in the MENA region, driven by increasing healthcare demands, government reforms, and a strategic focus on local production, improving access and affordability. Governments in countries like Saudi Arabia and the UAE are actively promoting the manufacturing of generics to reduce healthcare costs and strengthen local pharmaceutical industries. Key initiatives include partnerships between international companies and local producers, leading to investments in new facilities and joint ventures aimed at boosting capacity. Similarly, the UAE’s Ministry of Health and Prevention (MoHAP) has supported generic drug manufacturing by creating opportunities once patents for branded drugs expire.

The number of pharmaceutical manufacturing facilities in the UAE has risen from 4 in 2010 to 23 in 2022, reflecting robust growth. This number is expected to increase further in the coming years due to rising demand for affordable oncology treatments, increasing development and approval of biosimilars, the growing popularity of specialty generics, new product launches, and expanding government support through investments in healthcare infrastructure and research.

Technological advancements and an improved supply chain have further accelerated industry expansion. Innovations in manufacturing processes, including automation and advanced quality control systems, have enhanced production efficiency and output. Initiatives like the Mubadala Investment Company and G42 partnership in Abu Dhabi aim to establish a biopharmaceutical manufacturing hub, focusing on vaccines and therapeutic products for regional distribution. In fact, in March 2024, Mubadala Investment Company PJSC agreed to acquire KELIX Bio, aiming to enhance the UAE’s generics production capabilities, bolster its life sciences sector, and advance its economic diversification.

Additionally, the region’s ability to capitalize on expiring patents has positioned local manufacturers to compete effectively in the global market. While GCC countries drive value through branded and branded generic products, Africa contributes significantly to volume due to its waived patent protections and focus on cost-effective generics. This dual approach enables greater access to essential medicines while fostering regional industry growth.

The Rise of Biologics and Biosimilars

The MENA region is experiencing a substantial surge in the adoption and development of biologics and biosimilars, spurred by government initiatives, healthcare reforms, and rising demand for advanced therapies. Biologics, used primarily to treat complex conditions like autoimmune diseases and cancer, are increasingly supplemented by biosimilars due to their cost-effectiveness.

Governments in the region are actively supporting the biologics and biosimilars sectors. Saudi Arabia’s Vision 2030 emphasizes local production and innovation in pharmaceuticals, with initiatives such as the establishment of advanced R&D facilities and partnerships with international firms. The UAE has positioned itself as a regional hub for biopharmaceuticals, highlighted by Abu Dhabi’s Mubadala Investment Company’s recent ventures in complex generic and biosimilar production. Egypt is focusing on regulatory improvements, such as enhanced pharmacovigilance, to ensure the safety and efficacy of biosimilars​

Despite these advancements, the sector faces challenges, including inconsistent regulatory frameworks, limited infrastructure for large-scale production, and dependency on imported biologics. However, collaborative public-private partnerships and alignment with international regulatory standards, such as those of the EMA and FDA, are paving the way for a more robust ecosystem. These efforts are expected to improve access to affordable, life-saving therapies for patients across the MENA region, further solidifying its position in the global biologics and biosimilars market.

Economic Impact of Generics vs. Biologics

The economic impact of generics and biologics in the MENA region is becoming increasingly relevant as governments aim to enhance local pharmaceutical production and reduce healthcare costs. According to the World Health Organization (WHO), the MENA region has been focusing on improving access to essential medicines, with generics playing a vital role in this strategy. Generics are crucial for increasing affordability, as they are typically priced significantly lower than their branded counterparts. For example, the Egyptian Ministry of Health has implemented policies to promote the use of generics, which has led to a reduction in drug prices and improved access for patients. This initiative is part of a broader effort to ensure that essential medications are available at affordable prices across the region.

In addition to generics, biosimilars are emerging as an important component of the pharmaceutical landscape in MENA countries. The Saudi Food and Drug Authority (SFDA) has been actively working on regulatory frameworks to facilitate the approval and market entry of biosimilars. These efforts aim to provide patients with more affordable treatment options for complex diseases such as cancer and autoimmune disorders. The SFDA’s guidelines are designed to ensure that biosimilars meet stringent safety and efficacy standards while encouraging competition that can lead to lower prices. This regulatory support is essential for fostering a competitive market that benefits both patients and healthcare systems.

Also, The Pharmacy and Therapeutics Committee (PTC), comprising multidisciplinary experts, plays a key role in managing pharmacy inventories to improve patient care and reduce costs. The PTC evaluates drugs for formularies based on clinical, safety, ethical, and economic factors. In GCC countries, PTC committees assess medications using these criteria, ensuring cohesive medication-use policies. The committee also sets policies for prescribing, dispensing, and monitoring biosimilars, including decisions on switching or interchangeability. In countries like the UAE, KSA, and Qatar, formularies often pair biosimilars with brand names and batch numbers to streamline procurement and reimbursement processes.

Furthermore, various initiatives are underway across the MENA region to bolster the production and use of generics and biosimilars. For instance, the UAE’s National Strategy for Pharmaceuticals emphasizes local manufacturing capabilities, aiming to produce 50% of its medicines locally by 2030. This strategy not only focuses on generics but also includes biosimilars, reflecting a comprehensive approach to healthcare sustainability. Furthermore, regional collaborations among countries are being encouraged to harmonize regulations and share best practices, which can enhance market access for generics and biosimilars throughout the MENA region. These movements highlight a commitment from governments to improve healthcare access while addressing economic challenges associated with high drug prices.

Collaborations and Partnerships

The MENA region has seen various collaborations and partnerships aimed at enhancing the accessibility of biosimilars and generics for patients. Here are some key initiatives:

Public-Private Partnerships: Oman has been focusing on building a sustainable biopharmaceutical ecosystem through public-private partnerships. The government is actively seeking collaborations with international companies to boost local production of biosimilars. This strategy is essential for reducing dependence on imported biologics and enhancing the country’s export potential in the biopharmaceutical sector.

Hikma Pharmaceuticals and Celltrion: Hikma Pharmaceuticals has partnered with Celltrion to enhance access to essential medicines in the MENA region. This collaboration combines Hikma’s established commercial presence with Celltrion’s technical expertise, ensuring that innovative and reliable biosimilars are available to patients. The partnership also includes educational initiatives aimed at increasing healthcare professionals’ understanding and acceptance of biosimilars, which is crucial for improving patient outcomes.

Biocon and Tabuk Pharmaceuticals: In September 2024, Biocon Limited announced a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company, a leading pharmaceutical firm in the MENA region and a subsidiary of Astra Industrial Group. This collaboration will focus on commercializing Biocon’s GLP-1 products for diabetes and chronic weight management in select Middle Eastern countries. The agreement empowers Tabuk to manage marketing authorization and distribution in key markets like Saudi Arabia, UAE, Kuwait, and Jordan, aligning with Saudi Vision 2030 to localize pharmaceutical production and enhance healthcare access.

WHO Guidelines Adoption: The World Health Organization (WHO) has introduced revised guidelines for biosimilar approvals, which many MENA countries are beginning to adopt. However, there is still hesitancy among some nations to fully embrace these guidelines, which could facilitate faster market development for biosimilars. Egypt has taken the lead in adopting these new guidelines, while other countries are expected to follow as the demand for affordable biologics increases.

India’s Role as the Largest Exporter: India is the largest exporter of generic medicines and biosimilars to the MENA region. This dominance is driven by India’s ability to produce high-quality, cost-effective medications, which are crucial for enhancing access to affordable healthcare in developing economies. Initiatives like the Make in India campaign further support this growth by encouraging domestic manufacturing and fostering collaborations with MENA countries, thereby improving distribution networks and contributing to local economic development.

Regional Collaborations: The 2nd MENA Stakeholder Meeting on Biosimilars highlighted the importance of regional collaboration among stakeholders to establish a cohesive regulatory framework for biosimilars. This meeting brought together various stakeholders from different MENA countries to discuss best practices and strategies for improving market access for biosimilars.

These collaborations reflect a growing commitment in the MENA region to improve patient access to affordable medications through generics and biosimilars, driven by both local initiatives and international partnerships.

Case Studies from Key MENA Countries

Saudi Arabia

Saudi Arabia is making significant strides in its pharmaceutical industry through the National Biotechnology Strategy, which aims to position the country as a leader in biotechnology and biopharmaceuticals. The Saudi Food and Drug Authority (SFDA) has established a robust regulatory framework for biosimilars, closely aligning with guidelines from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). In 2024, the SFDA introduced incentives to promote local biopharmaceutical production, which is integral to the Kingdom’s Vision 2030 economic diversification plan. The focus on local manufacturing is expected to enhance self-sufficiency in healthcare and reduce reliance on imported medicines, thereby improving patient access to essential drugs.

United Arab Emirates

The UAE is at the forefront of personalized medicine through initiatives like the Emirati Genome Programme, which aims to map the genetic makeup of its population to tailor healthcare solutions. The Emirates Health Authority (EHA) has streamlined regulatory processes for biosimilars, introducing a fast-track approval system for those already approved by trusted international bodies. This regulatory approach not only facilitates quicker market entry for biosimilars but also encourages multinational companies to establish production facilities in the UAE. By fostering such collaborations, the UAE is positioning itself as a regional hub for biopharmaceutical innovation and personalized medicine.

Egypt

Egypt has made substantial progress in establishing itself as a hub for biosimilars through comprehensive regulatory advancements. The Egyptian Drug Authority (EDA) issued updated guidelines for biosimilar registration in 2020, which align with international standards set by organizations like WHO and EMA. These guidelines have facilitated the approval of several biosimilars, with four imported products licensed and numerous local candidates progressing toward market authorization. In 2024, the EDA emphasized post-marketing surveillance and pharmacovigilance, ensuring ongoing safety and efficacy monitoring of biosimilars in the market. Government incentives aimed at local manufacturers further strengthen Egypt’s position in the biosimilar landscape.

Jordan & Tunisia

Jordan has established a solid regulatory framework for biosimilars, adopting guidelines that reference EMA standards since 2015. The Jordan Food and Drug Administration (JFDA) ensures that biosimilar applications meet stringent quality and safety requirements, facilitating a conducive environment for local production. Similarly, Tunisia is emerging as a player in the generics market with its robust regulatory practices that support local pharmaceutical industries. Both countries are witnessing growth in their pharmaceutical sectors due to these frameworks, which encourage investment in generics and biologics while enhancing patient access to affordable medications.

Future Outlook: Challenges and Opportunities

The future of pharmaceuticals in the MENA region is poised for transformative growth, driven by ongoing innovations, collaborations, and regulatory advancements. Countries like Saudi Arabia, the UAE, and Egypt are leading the charge through initiatives such as Saudi Arabia’s Vision 2030, the UAE’s emphasis on personalized medicine, and Egypt’s strengthening of biosimilar regulations. These efforts are laying the groundwork for a robust pharmaceutical ecosystem that balances cost-effective healthcare with access to cutting-edge therapies.

However, the region faces key challenges. Regulatory inconsistencies among MENA countries can delay biosimilar adoption, while limited infrastructure in certain areas restricts large-scale production. Addressing these gaps will require regional collaboration to harmonize regulations, improve pharmacovigilance, and foster public-private partnerships.

Regulatory bodies like the Saudi Food and Drug Authority (SFDA), the UAE Ministry of Health and Prevention (MOHAP), and the Egyptian Drug Authority (EDA) are pivotal in maintaining high standards of safety and efficacy. The GCC Health Council’s push for unified drug policies further underscores the region’s dedication to developing a cohesive pharmaceutical framework.

With sustained efforts, MENA has the potential to become a global leader in pharmaceuticals, offering accessible, affordable, and innovative healthcare solutions. Strategic reforms, investment in research and development, and robust regional partnerships will enable the region to achieve its dual goals of economic growth and enhanced patient outcomes. This journey marks a critical step toward positioning MENA as a hub for global healthcare innovation.